Prognostic value of C-reactive protein-to-albumin ratio and inflammatory markers in esophageal cancer patients treated with chemoradiotherapy

Creative Commons License

Inanc B., MERMUT Ö.

Journal of Clinical Medicine of Kazakhstan, cilt.18, sa.2, ss.61-65, 2021 (Scopus)

Özet

Aim: This retrospective research was aimed to evaluate disease-free survival using inflammatory markers in esophageal cancer patients who received chemoradiotherapy. Material and methods: A total of 67 patients who received standard curative chemoradiotherapy for esophageal cancer were included in the study between 2011-2018. The patient, treatment characteristics, and pretreatment inflammatory markers were obtained from the patient's file. Results: Median follow up time was 18 months (6-72 months). ROC curve analyses showed the C-Reactive Protein/Albumin cut-off value 0.9 for disease-free survival (AUC: 78.8%; sensitivity: 85%; specificity: 67.5%). 2-year disease free survival for C-Reactive Protein/Albumin ≥0.9 and C-Reactive Protein/Albumin <0.9 were 45.7% and 78%, respectively (P=0.035). The radiation doses ≥50Gy (versus <50Gy, p=0.027) and C-Reactive Protein/Albumin ratio <0.9 (versus ≥0.9, p=0.005) appeared significant associates of better disease-free survival in univariate analyses, but the age, gender, stage, localization, neutrophil-to-lympocyte ratio and platelet-to-lymphocyte ratio were no statistically significant (p>0.005). On the multivariate logistic analysis, our results showed that C-Reactive Protein/Albumin <0.9 [hazard ratio 1.29; 95% confidence interval, 1.336-2.946; P=0.014]; and radiation dose-50 Gy (hazard ratio 0.91; 95% confidence interval, 1.229-4.997; P=0.027) independent prognostic indicators. Conclusion: Our study found that the C-Reactive Protein/Albumin ratio is easy to apply and maybe a promising marker to predict disease-free survival in esophageal cancer patients who received chemoradiotherapy.